Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences

NEXT STORY
Beroni Group Received Approval for 43.5% R&D Rebate from Australian Government for the Novel, Potential Anti-Cancer Drug PENAO
PREV STORY
Le Dr Benjamin Musher présidera l’étude de phase 1-2 évaluant le traitement anticancéreux Natrunix™ de XBiotech contre le cancer du pancréas
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Icosavax Initiates Phase 1/1b Trial of VLP Vaccine Candidate Against Respiratory Syncytial Virus

author_avatar
NASDAQ Market News

Amid the COVID-19 crisis and the looming economic recession, the Nanotechnology in Drug Delivery market worldwide will grow by a projected US$124.7 Billion, during the analysis period

author_avatar
NASDAQ Market News

OSE Immunotherapeutics Presents CLEC-1, Novel Myeloid Immune Checkpoint Target for Cancer Immunotherapy

author_avatar
NASDAQ Market News